• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

机构信息

Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.

DOI:10.1038/s41408-024-01000-2
PMID:38378617
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10879201/
Abstract

[Image: see text]

摘要

[图片：见正文]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ae/10879201/8eec364b3824/41408_2024_1000_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ae/10879201/1d50c83be902/41408_2024_1000_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ae/10879201/8eec364b3824/41408_2024_1000_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ae/10879201/1d50c83be902/41408_2024_1000_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ae/10879201/8eec364b3824/41408_2024_1000_Fig2_HTML.jpg

相似文献

1
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。
Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.
2
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.新型低甲基化剂NTX-301作为单一疗法及与维奈托克联合用于急性髓系白血病的临床前疗效
Blood Cancer J. 2022 Apr 11;12(4):57. doi: 10.1038/s41408-022-00664-y.
3
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
4
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.初治急性髓系白血病中对维奈托克加去甲基化药物反应的分子预测指标
Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.
5
Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.维奈托克与低甲基化药物用于治疗TP53基因变异的急性髓系白血病
Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.
6
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.急性髓系白血病中使用去甲基化药物联合维奈克拉进行异基因移植的结果。
Am J Hematol. 2022 Jun 1;97(6):E191-E194. doi: 10.1002/ajh.26524. Epub 2022 Mar 18.
7
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.新诊断的伴有或不伴有维奈托克治疗的 TP53 突变急性髓系白血病患者的结局。
Cancer. 2021 Oct 1;127(19):3541-3551. doi: 10.1002/cncr.33675. Epub 2021 Jun 28.
8
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
9
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.MDM2拮抗剂idasanutlin与Bcl-2抑制剂维奈托克在p53野生型急性髓系白血病模型中的卓越抗肿瘤活性。
J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3.
10
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.维奈克拉治疗急性髓系白血病：超越 VIALE-A。
Am J Hematol. 2024 Apr;99(4):515-518. doi: 10.1002/ajh.27256. Epub 2024 Feb 20.

引用本文的文献

1
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.AML60+评分对接受去甲基化药物治疗的老年急性髓系白血病患者的预后影响：一项回顾性多中心分析
Cancers (Basel). 2025 Aug 14;17(16):2658. doi: 10.3390/cancers17162658.
2
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.不适合接受治疗的新诊断急性髓系白血病患者：2026年治疗算法
Blood Cancer J. 2025 Aug 16;15(1):139. doi: 10.1038/s41408-025-01346-1.
3
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.

本文引用的文献

1
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.维奈托克持续时间（14 天、21 天和 28 天）联合低甲基化药物治疗初诊急性髓系白血病：疗效、毒性和生存的比较分析。
Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15.
2
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.维奈托克与低甲基化剂联合治疗初诊急性髓系白血病：301 例连续患者的反应和生存的基因型特征。
Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10.
3
依普奈妥单抗与阿扎胞苷联合治疗突变型骨髓增生异常综合征/急性髓系白血病患者的长期随访及2期联合研究结果
Hemasphere. 2025 Jul 13;9(7):e70164. doi: 10.1002/hem3.70164. eCollection 2025 Jul.
4
TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.TP53 突变型急性髓系白血病：未解之谜
Hematol Oncol. 2025 Jul;43(4):e70106. doi: 10.1002/hon.70106.
5
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.TP53 突变的急性髓系白血病缓解期患者接受异基因干细胞移植的障碍
Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590-6.
6
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.TP53 突变的髓系肿瘤：2024 年诊断、风险分层及管理更新
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):88-115. doi: 10.1002/ajh.27655. Epub 2025 Mar 11.
7
Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.骨髓增殖性肿瘤中的精准医学：挑战与机遇
J Pers Med. 2025 Jan 26;15(2):49. doi: 10.3390/jpm15020049.
8
Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.维奈托克添加到CLAG方案中可能会改善复发/难治性急性髓系白血病患者的预后。
Ther Adv Hematol. 2025 Feb 10;16:20406207251319603. doi: 10.1177/20406207251319603. eCollection 2025.
9
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53.伴有TP53突变的髓系肿瘤的非移植治疗方法
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):326-334. doi: 10.1182/hematology.2024000557.
10
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.使用质谱流式细胞术进行的T细胞免疫聚类分析可识别急性髓系白血病患者的独特亚组。
Blood Adv. 2025 Jan 28;9(2):239-243. doi: 10.1182/bloodadvances.2024014553.
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
接受首次诱导或挽救治疗后接受异基因干细胞移植的TP53突变急性髓系白血病患者的生存情况：髓系恶性肿瘤与肿瘤性疾病联盟（COMMAND）的结果
Leukemia. 2023 Apr;37(4):799-806. doi: 10.1038/s41375-023-01847-7. Epub 2023 Feb 18.
4
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.TP53 突变型骨髓增生异常综合征和急性髓系白血病：生物学、当前治疗和未来方向。
Cancer Discov. 2022 Nov 2;12(11):2516-2529. doi: 10.1158/2159-8290.CD-22-0332.
5
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.伴有或不伴有 TP53 突变的不良细胞遗传学患者接受 Venetoclax 和阿扎胞苷治疗的结局。
Clin Cancer Res. 2022 Dec 15;28(24):5272-5279. doi: 10.1158/1078-0432.CCR-22-1183.
6
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.初治急性髓系白血病中对维奈托克加去甲基化药物反应的分子预测指标
Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.
7
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。
Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.
8
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.TP53 突变型急性髓系白血病采用不断发展的一线治疗方案的结果：异基因干细胞移植对生存的影响。
Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.
9
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.70岁以上急性髓系白血病：强化化疗与HMA±维奈克拉化疗治疗后生存情况的回顾性比较
Am J Hematol. 2021 Apr 1;96(4):E108-E111. doi: 10.1002/ajh.26112.
10
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.基于 Venetoclax 的化疗在急性和慢性髓性肿瘤中的应用：文献综述和实践要点。
Blood Cancer J. 2020 Nov 23;10(11):122. doi: 10.1038/s41408-020-00388-x.